Introduction Treatment-resistant depression (TRD) is a serious and debilitating psychiatric
disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has …

Background Older, compared with younger, patients with treatment-resistant depression
(TRD) typically have lower response and remission rates with poorer tolerability to …

Background Elderly patients with major depression have a poorer prognosis, are less
responsive to treatment, and show greater functional decline compared with younger …

Aim: There is limited real-world evidence for patients with treatment-resistant depression
(TRD) receiving esketamine nasal spray. Methods: This retrospective cohort study used data …

Abstract Background Esketamine nasal spray (Spravato) in conjunction with oral
antidepressants (ADs) is approved in the European Union, United States, and other markets …

ABSTRACT Introduction: In March 2019, intranasal esketamine was approved by the Food
and Drug Administration (FDA) for the treatment of treatment-resistant depression (TRD) in …

Purpose To review the efficacy, safety, and place in therapy of intranasal esketamine, a
treatment modality for treatment-resistant depression. Summary An electronic literature …

Importance Approximately one-third of patients with major depressive disorder (MDD) do not
respond to available antidepressants. Objective To assess the efficacy, safety, and dose …

Objectives Despite the available therapies for treatment-resistant depression (TRD), there
are a limited number that are evidence-based and effective in this hard-to-treat population …

Purpose This Phase 3, multicenter study (NCT03434041) was conducted in primarily
Chinese patients with treatment-resistant depression (TRD) to support the registration of …